Adequate bladder pain syndrome (BPS) healthcare balances between organ specific and region specific (chronic pelvic pain) treatments. A multidisciplinary approach is essential to break-up the interactive negative spirals that are part of the condition. Nonetheless, BPS is not the only inflammatory condition in the bladder and, although rare, these conditions also warrant adequate guidance. In the last 10 years there has been an increased effort to identify BPS subpopulations and to develop more targeted treatments of our BPS subgroups.
In this webinar, we will provide the current information about stratification, glycosaminoglycan (GAG) layer and GAG therapy. On IC/BPS The trigger of Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS), the leaky urothelium, can be best treated by locally administered drugs of GAG-layer compounds. Just a small portion of IC/BPS patients (around 15-20%) accept instillation therapy, due to the high treatment costs and the painful catheterization. Recently there are new treatment options available, preventing these dissuasive factors. We give the basic answers to the why, what, how and when.
- Publication date: November 2020
- Available languages: English
- Topic: Chronic Pelvic Pain
- CME: 1 European CME credits (ECMEC)
- Duration: Approx. 60 – 90 minutes